Anthem Biosciences IPO
LiveAlready have an account? Apply now
Schedule of Anthem Biosciences
| Issue open date | 14 Jul 2025 |
| Issue close date | 16 Jul 2025 |
| UPI mandate deadline | 16 Jul 2025 (5 PM) |
| Allotment finalization | 17 Jul 2025 |
| Refund initiation | 18 Jul 2025 |
| Share credit | 18 Jul 2025 |
| Listing date | 21 Jul 2025 |
| Mandate end date | 31 Jul 2025 |
| Lock-in end date for anchor investors (50%) | 16 Aug 2025 |
| Lock-in end date for anchor investors (remaining) | 15 Oct 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Anthem Biosciences
Anthem Biosciences, established in 2006, is an innovation-driven Contract Research, Development, and Manufacturing Organisation (CRDMO) that offers integrated services in drug discovery, development, and manufacturing. The company specialises in fermentation-based APIs, including probiotics, enzymes, peptides, and biosimilars, catering to both biotech startups and large pharma worldwide. With 196 active projects, including 170 discovery projects, Anthem’s R&D spans RNAi, ADCs, and peptides. The company’s manufacturing facilities, including one under construction, support a broad portfolio of custom synthesis and fermentation capabilities. Known for green chemistry and cutting-edge technologies, Anthem is a leader in delivering sustainable, high-quality solutions across regulated markets.
Financials of Anthem Biosciences
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹3395 crores |
| Offer for sale | ₹3395 crores |
Strengths
- Comprehensive services across the drug life cycle for small molecules and biologics
- Focus on advanced solutions across modalities and manufacturing practices
- Specialised model for small pharmaceutical and biotech companies
- Established customer base with ongoing relationships
- Experienced leadership and skilled scientific team
Risks
- Failure to develop new or improve existing technologies.
- Delays in obtaining regulatory approvals.
- Under-utilisation of manufacturing capacity and demand forecasting issues.
- Pricing pressures affecting product prices and profitability.
- Risks from data security breaches and failure to safeguard sensitive information.
- Seasonality affecting business performance and cash flow.
Allotment Status for Anthem Biosciences
To check your allotment status – click here.
Subscription Figures for Anthem Biosciences
Subscription numbers as of 5:00 PM on 15 July 2025:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 118.83 | 74.06 | 0.62x |
| NII | 89.12 | 914.42 | 10.26x |
| Retail | 207.95 | 458.79 | 2.21x |
| Employees | 1.58 | 4.34 | 2.74x |
| Total | 417.50 | 1451.62 | 3.48x |